A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a Tri-specific Antibody Targeting PD-1/VEGFA/CTLA-4, as Monotherapy and Combination Therapy in Participants With Advanced Solid Tumors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Jingru Wang
- Phone Number: +86 18017113282
- Email: wangjingru@cstonepharma.com
Study Locations
-
-
-
Melbourne, Australia
- Recruiting
- Alfred Hospital (Alfred Health)
-
Melbourne, Australia
- Recruiting
- Austin Hospital (Austin Health)
-
Melbourne, Australia
- Recruiting
- Monash Medical Centre (Monash Health)
-
Melbourne, Australia
- Recruiting
- Peter Maccallum Cancer Centre Research
-
South Brisbane, Australia
- Recruiting
- ICON Cancer Centre South Brisbane
-
Sydney, Australia
- Recruiting
- Macquarie University Hospital
-
Sydney, Australia
- Recruiting
- Blacktown Hospital
-
Sydney, Australia
- Recruiting
- Scientia Clinical Research LTD
-
-
-
-
-
Beijing, China
- Recruiting
- Beijing Cancer Hospital
-
Changchun, China
- Recruiting
- Jilin cancer hospital
-
Changsha, China
- Recruiting
- Hunan Cancer Hospital
-
Chengdu, China
- Recruiting
- West China Hospital of Sichuan University
-
Chengdu, China
- Recruiting
- Sichuan Cancer Hospital
-
Fuzhou, China
- Recruiting
- Fujian Cancer Hospital
-
Guangzhou, China
- Recruiting
- Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
-
Guangzhou, China
- Recruiting
- Sun Yat-sen University Cancer Center
-
Hangzhou, China
- Recruiting
- Zhejiang Cancer Hospital
-
Hangzhou, China
- Not yet recruiting
- The First Affiliated Hospital, Zhejiang University School of Medicine
-
Harbin, China
- Recruiting
- Harbin Medical University Cancer Hospital
-
Hefei, China
- Recruiting
- Anhui Provincial Hospital
-
Jinan, China
- Recruiting
- Central Hospital Affiliated to Shandong First Medical University
-
Linyi, China
- Recruiting
- Linyi Cancer Hospital
-
Nanchang, China
- Recruiting
- The First Affiliated Hospital of Nanchang University
-
Nanjing, China
- Recruiting
- Nanjing Drum Tower Hospital
-
Shanghai, China
- Recruiting
- Fudan University Shanghai Cancer Center
-
Shanghai, China
- Recruiting
- Shanghai Pulmonary Hospital
-
Shanghai, China
- Recruiting
- Shanghai East Hospital
-
Wuhan, China
- Recruiting
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Xuzhou, China
- Recruiting
- Xuzhou Central Hospital
-
Zhengzhou, China
- Recruiting
- Henan Cancer Hospital
-
Zhengzhou, China
- Recruiting
- The First Affiliated Hospital of Zhengzhou University
-
-
-
-
California
-
Los Angeles, California, United States, 90025
- Recruiting
- START Los Angeles, LLC
-
-
Texas
-
Irving, Texas, United States, 75039
- Recruiting
- NEXT Dallas
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Evidence of a personally signed and dated informed consent document.
- Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- Age ≥ 18 years on the day of signing informed consent.
Phase I:
- Pathologically or cytologically confirmed, unresectable advanced solid tumors, including but not limited to non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), gastric cancer (GC), ovarian cancer (OC), cervical cancer (CC), etc.
- Failure of established standard of care for advanced disease, or no available standard of care.
Phase II:
- Pathologically or cytologically confirmed unresectable advanced solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), etc.
- Participants with at least one measurable lesion as defined per RECIST v1.1 solid tumor.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate organ function.
- Fertile male participants and female participants of childbearing potential must be willing to use an effective method of birth control from providing signed consent and for 180 days after the last investigational product administration.
- Female participants of childbearing potential must have a negative pregnancy test ≤ 7 days prior to the first dose of the investigational product.
Exclusion Criteria:
- History of a second malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured.
- Known primary central nervous system (CNS) tumor or solid tumor CNS metastasis that is either symptomatic, untreated, or requires therapy.
- Presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage within 4 weeks prior to the first dose of investigational product.
- Receipt of systemic corticosteroid treatment or any other form of immune suppressing treatment within 7 days prior to the first dose of investigational product.
- Active or prior history of definite inflammatory bowel disease.
- History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, or presence of active or suspected ILD/pneumonitis.
- Active infections requiring systemic therapy within 2 weeks prior to the first dose of investigational product.
- Positive for human immunodeficiency virus (HIV) or presence of acquired immune deficiency syndrome (AIDS).
- Active Hepatitis B or C infection.
- Active pulmonary tuberculosis (TB).
- Major surgery, chemotherapy, definitive radiotherapy, target therapy, immunotherapy, or other anti-cancer therapy within 21 days prior to the first dose of investigational product.
- Palliative radiotherapy within 14 days prior to the first dose of investigational product, or receipt of radioactive drug within 56 days prior to the first dose of investigational product.
- Administration of live vaccine within 28 days prior to the first dose of investigational product.
- History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- Receipt of antitumor Chinese herbal preparations or Chinese patent medicine within 7 days prior to the first dose of investigational product.
- Receipt of any other investigational drugs within 21 days prior to the first dose in this trial.
- History of hypersensitivity or idiosyncrasy to the excipients of the study drug or any monoclonal antibody.
- Any toxic effects of prior therapy or surgical procedures unresolved to baseline severity or NCI-CTCAE Version 5.0 Grade ≤ 1.
- Active alcohol or drug abuse.
- Female participants who are pregnant or breastfeeding.
- Other acute or chronic medical or psychiatric conditions that may increase the risk associated with study participation or investigational product administration.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dose Escalation
Participants will be administered escalating doses of CS2009.
|
CS2009 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W).
CS2009 will be administered via intravenous (IV) infusion on Day 1 of repeated 14/21-day cycles (Q2W/Q3W).
|
|
Experimental: Dose Expansion
Participants will be administered the recommended dose(s) of CS2009 with or without chemotherapy according to dose-escalation data.
|
IV infusion
IV infusion
IV infusion
IV infusion
IV infusion
IV infusion
IV infusion
IV infusion
IV infusion
IV infusion
IV infusion
IV infusion
CS2009 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W).
CS2009 will be administered via intravenous (IV) infusion on Day 1 of repeated 14/21-day cycles (Q2W/Q3W).
oral tablets
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
[Dose Escalation] Maximum tolerated dose (MTD) of CS2009
Time Frame: Cycle 1 (Up to 21 Days)
|
Participants will receive CS2009 via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W).
The MTD will be determined, if any, by the number of participants who experience a dose limiting toxicity (DLT).
|
Cycle 1 (Up to 21 Days)
|
|
[Dose Escalation] Tentative recommended Phase II dose (RP2D) of CS2009
Time Frame: Cycle 1 (Up to 21 Days)
|
The selection of tentative RP2D will be based on consideration of overall safety information together with available pharmacokinetic, pharmacodynamic, and efficacy data.
The tentative RP2D may be the MTD or a lower dose within the tolerable dose range.
|
Cycle 1 (Up to 21 Days)
|
|
[Dose Escalation] Number of participants with adverse events (AEs)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
[Dose Expansion] Objective response rate (ORR) evaluated by investigators per RECIST v1.1
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
[Dose Escalation & Expansion] Area under the curve (AUC) of CS2009
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Maximum concentration (Cmax) of CS2009
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Elimination half-life (t1/2) of CS2009
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Minimum concentration (Cmin) of CS2009
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Number of participants with anti-CS2009 antibodies
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation] Objective response rate (ORR) evaluated by investigators per RECIST v1.1
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Expansion] Number of participants with adverse events (AEs)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Amino Acids, Peptides, and Proteins
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Nucleic Acids, Nucleotides, and Nucleosides
- Hydrocarbons
- Cycloparaffins
- Hydrocarbons, Alicyclic
- Hydrocarbons, Cyclic
- Terpenes
- Carbohydrates
- Camptothecin
- Alkaloids
- Podophyllotoxin
- Tetrahydronaphthalenes
- Naphthalenes
- Polycyclic Aromatic Hydrocarbons
- Hydrocarbons, Aromatic
- Polycyclic Compounds
- Glucosides
- Glycosides
- Enzymes and Coenzymes
- Inorganic Chemicals
- Chlorine Compounds
- Nitrogen Compounds
- Coordination Complexes
- Guanine
- Hypoxanthines
- Purinones
- Purines
- Glutamates
- Amino Acids, Acidic
- Amino Acids
- Amino Acids, Dicarboxylic
- Taxoids
- Cyclodecanes
- Diterpenes
- Deoxycytidine
- Cytidine
- Pyrimidine Nucleosides
- Pyrimidines
- Nucleosides
- Formyltetrahydrofolates
- Tetrahydrofolates
- Folic Acid
- Pterins
- Pteridines
- Uracil
- Pyrimidinones
- Coenzymes
- Platinum Compounds
- Deoxyribonucleosides
- Docetaxel
- Capecitabine
- Oxaliplatin
- Irinotecan
- Pemetrexed
- Gemcitabine
- Fluorouracil
- Etoposide
- Carboplatin
- Leucovorin
- Paclitaxel
- Cisplatin
- 130-nm albumin-bound paclitaxel
Other Study ID Numbers
Other Study ID Numbers
- CS2009-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.